Core binding factor acute myelogenous leukemia-2021 treatment algorithm

Blood Cancer J. 2021 Jun 16;11(6):114. doi: 10.1038/s41408-021-00503-6.


Core binding factor acute myelogenous leukemia (CBF-AML), characterized by the presence of either t(8;21) (q22;q22) or inv(16) (p13q22)/t(16;16), is considered good-risk AML in the context of cytarabine based intensive chemotherapy. Still, outcome can be improved significantly through the effective implementation of available therapeutic measures and appropriate disease monitoring. The incorporation of gemtuzumab ozogamicin into frontline therapy should be standard. Cytarabine based induction/consolidation regimen may be combined with anthracycline (3 + 7 standard) or antimetabolite, fludarabine. Serial quantitative polymerase chain reaction (QPCR) monitoring of unique fusion transcripts allows monitoring for measurable residual disease clearance; this allows for better prognostication and well as treatment modifications.

Publication types

  • Review

MeSH terms

  • Algorithms*
  • Anthracyclines / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chromosome Inversion
  • Chromosomes, Human / genetics
  • Chromosomes, Human / metabolism
  • Core Binding Factors* / blood
  • Core Binding Factors* / genetics
  • Cytarabine / therapeutic use
  • Disease-Free Survival
  • Humans
  • Leukemia, Myeloid, Acute* / blood
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Neoplasm Proteins* / blood
  • Neoplasm Proteins* / genetics
  • Neoplasm, Residual
  • Translocation, Genetic


  • Anthracyclines
  • Core Binding Factors
  • Neoplasm Proteins
  • Cytarabine